• Group sales revenue for 2025 increased by 7.6% in constant currencies to approximately €3.5 billion.
• Underlying EBITDA margin rose to 29.7%, up from 28.0% in the prior year.
• The company forecasts sales growth of 5% to 9% for fiscal year 2026.
GÖTTINGEN, Germany – The life science market is showing signs of normalization. Sartorius closed fiscal year 2025 with a considerable increase in sales revenue and earnings, reporting a 7.6 percent rise in constant-currency sales to 3.538 billion euros.
The company also issued a positive growth forecast for 2026.
This story was produced and verified by our AI-powered newsroom. Learn more about our process.
What is new?
According to preliminary figures for fiscal year 2025, the life science group Sartorius reported considerable growth in sales revenue and earnings. The company achieved its financial targets for the year, with both of its divisions contributing to the results. CEO Dr. Michael Grosse noted that 2025 was characterized by a return to normal demand for consumables and continued cautious investment by customers. The business with equipment and instruments stabilized over the course of the year. The company’s management forecasts further profitable growth for 2026.
Key Financials for 2025
Sartorius Group’s sales revenue increased by 7.6 percent in constant currencies to 3.538 billion euros. All regions contributed to growth, with the Americas and Asia/Pacific regions both growing by 8.9 percent, and the EMEA region growing by 5.8 percent. Underlying EBITDA grew by 11.2 percent to 1.052 billion euros, with the corresponding margin rising to 29.7 percent from 28.0 percent in the previous year. Underlying net profit increased by 18.2 percent to 331 million euros.
The company’s equity ratio increased to 39.8 percent, and the ratio of net debt to underlying EBITDA declined to 3.55. Investments in research and production infrastructure totaled 442 million euros, representing 12.5 percent of sales revenue.
Divisional Performance
The Bioprocess Solutions Division saw its sales revenue rise by 9.5 percent in constant currencies to 2.865 billion euros, driven by strong demand for consumables. The division’s underlying EBITDA margin expanded by 2.4 percentage points to 31.7 percent. The company launched new products for process intensification, filtration, and cell therapies, and made progress in eco-design, including a PFAS-free filter.
The Lab Products & Services Division recorded sales revenue of 673 million euros, a slight increase of 0.2 percent in constant currencies, showing recovery in the second half of the year. Business with laboratory consumables and services grew, while the instrument business stabilized. The division’s underlying EBITDA margin was 21.5 percent, down from 22.9 percent, influenced by currency, product mix, and tariff effects. The acquisition of microtissue specialist MATTEK in July 2025 contributed to the division’s performance.
Outlook for 2026
For fiscal year 2026, Sartorius management forecasts continued profitable growth. The group anticipates sales revenue growth in constant currencies between 5 and 9 percent, with an underlying EBITDA margin expected to be slightly above 30 percent. The forecast includes a contribution of about 1 percentage point from the MATTEK acquisition. The ratio of capital expenditures to sales is projected to be similar to 2025, at around 12.5 percent.
For its divisions, the company expects the Bioprocess Solutions Division to grow between 6 and 10 percent, with a margin slightly above 32 percent. The Lab Products & Services Division is projected to grow between 2 and 6 percent, with a margin slightly below 21 percent, impacted by investments in the Advanced Cell Models business.
About this company
Sartorius is a leading international partner to the biopharmaceutical research and manufacturing industries. The Lab Products & Services Division focuses on innovative laboratory instruments and consumables for research and quality assurance laboratories in pharmaceutical and biopharmaceutical companies as well as academic research institutions. The Bioprocess Solutions Division supports customers with a broad product portfolio focused on single-use solutions for the safer, faster, and more sustainable production of biotech drugs, vaccines, and cell and gene therapies.
With around 60 production and sales locations worldwide, the Göttingen-based company has a strong global presence. Sartorius regularly supplements its portfolio with acquisitions of complementary technologies. At the end of 2025, the company employed more than 14,000 people.
Read more
Sartorius and TheWell Bioscience to Develop Hydrogels and Bioinks